Recruiting
Gastrooesophageal cancer+6
RecruitingStudy of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers
Registered drugNo placebo
Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers
Registered drugNo placebo
- Disease:Gastrooesophageal cancerGastric cancer+5
- Substances:Glatiramer AcetateHUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Glatiramer Acetate
- Sponsor:Genmab A/S
